Cancer Metabolism Core
Cancer Metabolism Core
批准号:
10518246
负责人:
Pankaj Kumar Singh
金额:
$9.64万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-20 至 2027-08-31
关键词:
AddressBiological AssayCarbonCell LineCellsClustered Regularly Interspaced Short Palindromic RepeatsCollaborationsCommunicationCommunity NetworksComplexCoupledData AnalysesData ScientistDependenceDrug KineticsEnsureGas ChromatographyGas-Liquid ChromatographyGenomic LibraryGenus HippocampusGoalsHumanInformation DisseminationInfrastructureIntercellular FluidInvestigationKineticsLabelLeadershipLibrariesLiquid ChromatographyMalignant neoplasm of pancreasMass Spectrum AnalysisMeasuresMediator of activation proteinMedical centerMetabolicMetabolic PathwayMetabolismMethodsMusNebraskaOrganoidsOxygen ConsumptionPancreatic Ductal AdenocarcinomaPatientsPharmaceutical PreparationsPharmacodynamicsPhysiologicalPublicationsPublishingQuality ControlResearch PersonnelResistanceSamplingServicesSignal TransductionSpecimenStable Isotope LabelingStatistical MethodsStromal NeoplasmTestingTissuesTrainingTumor TissueUniversitiesWorkbasecancer cellchemotherapycost effectivedata managementdesigneffective therapyexosomeexperimental studyextracellularfollow-upgenetic manipulationhuman tissueimprovedinnovationlarge scale datalipidomicsmembermetabolomicsneoplastic cellnovelnovel therapeuticsonline resourcepatient prognosisprogramsscreeningstable isotopetandem mass spectrometrytherapy resistantthree dimensional cell culturetumortumor metabolismwhole genome
中文摘要
代谢核心
摘要
拟议的UNMC获得性耐药治疗网络(ARTNet)中心的代谢核心,
胰腺癌(ACPC)将研究创新的,假设驱动的代谢和信号传导机制
导致胰腺导管腺癌(PDAC)获得性耐药的改变。核心
代谢核心提供的服务将很好地融入所有三个项目。核心将提供
为所有项目提供具有成本效益的代谢组学和数据分析支持,并进行适当的质量控制,
提供代谢组学、生理分析和代谢分析方面的集中基础设施和专业知识,
依赖/漏洞屏幕。新陈代谢核心将有三个具体目标。基础能力
核心提供的技术将包括稳态极性代谢组学和脂质组学(具体目标1),稳定同位素
解析代谢组学(SIRM)与动力学通量分析(特定目标2)和海马细胞外通量
基于分析仪的测定、研究细胞代谢状态的荧光测定,以及鉴定代谢产物的方法。
具体目标3(Specific Aim 3)代谢中心将参与稳态的设计和实施
极性代谢组学、脂质组学、13 C-代谢物标记的细胞系动力学通量分析、类器官和
外来体该核心还将为小鼠和人类进行稳态极性代谢组学和脂质组学研究
所有项目的肿瘤组织标本。该核心还将根据需要为ACPC提供实践培训,
其他ARTNet中心和其他研究人员。核心还将为测量药物提供支持。
组织中的浓度和代谢以及药物药代动力学/药效学研究。
英文摘要
METABOLISM CORE
Abstract
The metabolism core of the proposed the UNMC Acquired Resistance to Therapy Network (ARTNet) Center for
Pancreatic Cancer (ACPC) will study innovative, hypothesis-driven mechanisms of metabolic and signaling
alterations that contribute to acquired therapy resistance in pancreatic ductal adenocarcinoma (PDAC). The core
services provided by the metabolism core will be well integrated into all the three projects. The core will offer
cost-effective metabolomics and data analysis support with appropriate quality controls for all projects by
providing a centralized infrastructure and expertise in metabolomics, physiological assays, and metabolic
dependency/vulnerability screens. The metabolism core will have three specific aims. The basic capabilities
offered by the Core will include steady-state polar metabolomics and lipidomics (Specific Aim 1), Stable Isotope
Resolved Metabolomics (SIRM) with kinetic flux analysis (Specific Aim 2), and Seahorse extracellular flux
analyzer-based assays, fluorescent assays to investigate the metabolic state of cells, and identifying metabolic
vulnerabilities (Specific Aim 3). The Metabolism Core will participate in the design and conduct of steady-state
polar metabolomics, lipidomics, 13C-metabolite labeled kinetic flux analysis with cell lines, organoids, and
exosomes. The core will also perform steady-state polar metabolomics and lipidomics for mouse and human
tumor tissue specimens in all the projects. The core will also provide hands-on training, as needed, for the ACPC,
other ARTNet centers, and other investigators. The core will also provide support for measuring drug
concentrations and metabolism in the tissues and drug pharmacokinetics/ pharmacodynamics studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
-
批准号:10518247
-
项目类别:
-
资助金额:$29.39万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Pancreatic Cancer ARTNet Center
-
批准号:10707504
-
项目类别:
-
资助金额:$126.6万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Administrative Core
-
批准号:10518244
-
项目类别:
-
资助金额:$11.83万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Cancer Metabolism Core
-
批准号:10707540
-
项目类别:
-
资助金额:$9.37万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Pancreatic Cancer ARTNet Center
-
批准号:10518243
-
项目类别:
-
资助金额:$128.43万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Metabolic regulation of FOLFIRINOX acquired resistance in pancreatic cancer
-
批准号:10707541
-
项目类别:
-
资助金额:$24.65万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Administrative Core
-
批准号:10707537
-
项目类别:
-
资助金额:$30.72万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Molecular Basis of ME2-mediated Tumor Suppression in Pancreatic Cancer
-
批准号:10671029
-
项目类别:
-
资助金额:$42.2万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression
-
批准号:10363987
-
项目类别:
-
资助金额:$65.54万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Mitochondrial calcium signaling in pancreatic cancer metastasis and progression
-
批准号:10565949
-
项目类别:
-
资助金额:$62.77万
-
财政年份:2022
-
负责人:Pankaj Kumar Singh
-
依托单位:
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis
-
批准号:10203864
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2018
-
负责人:Pankaj Kumar Singh
-
依托单位:
Project 3: MUC16-Mediated Metabolic Reprograming Induces PC Metastasis
-
批准号:10413940
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2018
-
负责人:Pankaj Kumar Singh
-
依托单位:
Metabolic Regulation of Tumor Progression, Metastasis and Chemoresistance by SIRT5/ELK3 signaling in Pancreatic Cancer
-
批准号:10662933
-
项目类别:
-
资助金额:$0.09万
-
财政年份:2017
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer
-
批准号:10630681
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2016
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting the Metabolic Basis of Cachexia in Pancreatic Cancer
-
批准号:10053712
-
项目类别:
-
资助金额:$43.41万
-
财政年份:2016
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting MUC1-induced Tumor-stromal Metabolic Cross-talk in Pancreatic Cancer
-
批准号:8370711
-
项目类别:
-
资助金额:$42.86万
-
财政年份:2012
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer
-
批准号:10738314
-
项目类别:
-
资助金额:$5.48万
-
财政年份:2012
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer
-
批准号:10630607
-
项目类别:
-
资助金额:$44.09万
-
财政年份:2012
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer
-
批准号:10679793
-
项目类别:
-
资助金额:$5.48万
-
财政年份:2012
-
负责人:Pankaj Kumar Singh
-
依托单位:
Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer
-
批准号:10684833
-
项目类别:
-
资助金额:$44.09万
-
财政年份:2012
-
负责人:Pankaj Kumar Singh
-
依托单位:
海外基金